Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB).
The Food and Drug Administration (FDA) approved ProAir Digihaler in December 2018. The product is the first digital rescue inhaler with albuterol that contains a built-in electronic module with a QR code located on top of the inhaler to detect, record and store data on inhaler use. It may be used with, and transmits information to, the ProAir® Digihaler® app through Bluetooth® wireless technology. The electronic module does not control or interfere with the delivery of the medication through the inhaler.
Patients will be able to review the data on the mobile app and share it with their healthcare provider. The app provides features to patients such as daily and weekly reports on inhaler use, inspiratory flow rates, and local environment conditions (eg, pollen count forecast). It also sends notifications to patients if their inhalation technique needs improvement or if they have used their inhaler more than 12 times in a 24-hour period.
The ProAir Digihaler is supplied as 117mcg of albuterol sulfate from the device reservoir (108mcg from the mouthpiece) per actuation; the inhaler contains 200 actuations with a metered-dose counter. The Wholesale Acquisition Cost (WAC) is $146.67 per inhaler. The Company also offers a copay savings card for eligible patients.
“The launch of ProAir® Digihaler® and its companion app provides a great opportunity for bringing a new digital health tool to asthma and COPD patients in the US,” said Brendan O’Grady, Executive Vice President, North America Commercial at Teva Pharmaceuticals. “We are especially proud to provide our first Digihaler® product at a time when digital health technology is growing and continues to transform patient care, since it will enable patients to electronically record and monitor their rescue inhaler use.”
The Company’s Digihaler portfolio also includes the AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder, which are expected to become available later this year.
For more information visit proairdigihaler.com.
